U.S. private equity firm Audax Private Equity has acquired Altasciences Company Inc, a Laval, Québec-based early-phase clinical research organization (CRO) operating across North America. No financial terms were disclosed for the deal, which was done by Audax in partnership with the company’s management. The seller is Canadian private equity firm Kilmer Capital Partners, which invested in Altasciences in 2007. Altasciences combines Algorithme Pharma, Vince & Associates and Algorithme Pharma USA. The latter two companies were added-on with Kilmer’s support. Audax said it will back Altasciences’ continued organic and acquisition-led growth.
Audax Private Equity Announces the Acquisition of Altasciences Clinical Research
June 13, 2017
BOSTON–(BUSINESS WIRE)–Audax Private Equity (“Audax”) announced that it has partnered with management to acquire Altasciences Company, Inc. (“Altasciences”), a leading early phase contract research organization (CRO) in North America. Audax acquired Altasciences from Kilmer Capital Partners, a private equity firm based in Toronto, Canada. Terms of the transaction were not disclosed.
Altasciences, headquartered in Laval, Quebec, encompasses Algorithme Pharma, Vince & Associates Clinical Research, and Algorithme Pharma USA. Altasciences offers expertise in the execution of a wide range of New Drug Application (NDA) enabling clinical trials and support services including data management, biostatistics, medical writing, and bioanalysis.
Geoffrey S. Rehnert, Co-Chief Executive Officer, Audax Group, said, “Altasciences is a leader in the early phase clinical research industry. We look forward to working with Chris Perkin and the Altasciences team to continue building a leading platform through organic growth and add-on acquisitions.”
Chris Perkin, Chief Executive Officer, Altasciences, said “We are excited to be partnering with Audax for the next stage of our growth. Audax brings expertise and resources that will help us continue to build our market leadership position by expanding our service offering and value proposition to our clients through strategic acquisitions and growth initiatives.”
Fairmount Partners served as financial advisor to Altasciences. Blake, Cassels & Graydon, LLP and Kirkland & Ellis, LLP served as counsel to Audax.
ABOUT AUDAX PRIVATE EQUITY
Since its founding in 1999, Audax Private Equity has been focused on building leading middle market companies. Audax has invested $4 billion in 105 platform and 573 add-on companies. Through its disciplined Buy & Build approach, Audax seeks to help platform companies execute add-on acquisitions that fuel revenue growth, optimize operations, and significantly increase equity value. Audax Private Equity is an integral part of Audax Group, an alternative asset management firm specializing in investments in middle market companies. With offices in Boston, New York, and San Francisco, Audax Group has over $11 billion in assets under management across its Private Equity, Mezzanine, and Senior Debt businesses. For more information, visit the Audax Group website, www.audaxgroup.com.
Geoffrey S. Rehnert, 617-859-1503
Co-Chief Executive Officer
Altasciences Clinical Research
Chris Perkin, 450-973-5300
Photo courtesy of Altasciences Company Inc